Hydroxypropyl betadex - CTD Holdings

Drug Profile

Hydroxypropyl betadex - CTD Holdings

Alternative Names: HP-Beta-CD - CTD Holdings; HP-β-CD - CTD Holdings; Hydroxypropyl-beta-cyclodextrin - CTD Holdings; Trappsol Cyclo; Trappsol® Hydroxypropyl Beta Cyclodextrin-Endotoxin Controlled (THPB-EC) grade - CTD

Latest Information Update: 09 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CTD Holdings
  • Class Antidementias; Antivirals; Beta-Cyclodextrins; Peripheral vasodilators; Vascular disorder therapies
  • Mechanism of Action Binding agents; Cholesterol modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Niemann-Pick disease type C
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Niemann-Pick disease type C
  • Preclinical Alzheimer's disease
  • Research Diabetic nephropathies; Peripheral arterial disorders; Viral infections

Most Recent Events

  • 03 Oct 2018 Adverse events and pharmacodynamics data from phase I and phase I/II trials in Niemann-Pick disease type C released by CTD Holdings
  • 23 Aug 2018 CTD Holdings announces intention to submit regulatory applications seeking marketing authorisation for Niemann-Pick disease type C
  • 28 Jul 2018 No recent reports of development identified for clinical-Phase-Unknown development in Niemann-Pick-disease-type-C in Brazil (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top